BDBM243402 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)pyrimidine-2,4-diamine::US10053458, 34

SMILES COc1cc2CCNCc2cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1

InChI Key InChIKey=ZTQDHDMZXGLFHJ-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 243402   

TargetALK tyrosine kinase receptor(Human)
Korea Research Institute of Chemical Technology

US Patent
LigandPNGBDBM243402(5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-me...)
Affinity DataIC50: 1nMT: 2°CAssay Description:A proliferation inhibitory activity against the ALK of the compound represented by Chemical Formula 1 according to the present invention at an enzyme...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2018
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor [L1196M](Human)
Korea Research Institute of Chemical Technology

US Patent
LigandPNGBDBM243402(5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-me...)
Affinity DataIC50: 10nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2018
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Korea Research Institute of Chemical Technology

US Patent
LigandPNGBDBM243402(5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-me...)
Affinity DataIC50: 1nMAssay Description:Inhibition of ALK (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetALK tyrosine kinase receptor(Human)
Korea Research Institute of Chemical Technology

US Patent
LigandPNGBDBM243402(5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-me...)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of crizotinib-resistant ALK G1202R mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescenc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetALK tyrosine kinase receptor(Human)
Korea Research Institute of Chemical Technology

US Patent
LigandPNGBDBM243402(5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-me...)
Affinity DataIC50: 7nMAssay Description:Inhibition of crizotinib-resistant ALK L1196M mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescenc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetALK tyrosine kinase receptor(Human)
Korea Research Institute of Chemical Technology

US Patent
LigandPNGBDBM243402(5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-me...)
Affinity DataIC50: 0.240nMAssay Description:Inhibition of crizotinib-resistant ALK G1269A mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescenc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetALK tyrosine kinase receptor(Human)
Korea Research Institute of Chemical Technology

US Patent
LigandPNGBDBM243402(5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-me...)
Affinity DataIC50: 0.460nMAssay Description:Inhibition of crizotinib-resistant ALK F1174L mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescenc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetALK tyrosine kinase receptor(Human)
Korea Research Institute of Chemical Technology

US Patent
LigandPNGBDBM243402(5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(6-me...)
Affinity DataIC50: 0.450nMAssay Description:Inhibition of crizotinib-resistant ALK C1156Y mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescenc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed